HemeOncLinx News http://www.mdlinx.com/HemeOncLinx/news.cfm/newspage/1/spec_id/17/subspec_id/0 en-us Copyright 2009 MDLinx, Inc. <![CDATA[Objectively measured physical activity and sedentary time of breast cancer survivors, and associations with adiposity: Findings from NHANES (2003-2006)]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940743 11/9/2009 Cancer Causes and Control]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940743 <![CDATA[Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2934524 11/9/2009 Breast Cancer Research and Treatment]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2934524 <![CDATA[Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2943221 11/9/2009 Cancer Causes and Control]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2943221 <![CDATA[Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study ]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940859 11/9/2009 Journal of Clinical Oncology]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940859 <![CDATA[A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2935341 11/9/2009 Cancer]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2935341 <![CDATA[EFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2942272 11/9/2009 International Journal of Cancer]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2942272 <![CDATA[Continuous 5-fluorouracil infusion plus long acting Octreotide in advanced well differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network.]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2939475 11/9/2009 BMC Cancer]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2939475 <![CDATA[Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia ]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940861 11/9/2009 Journal of Clinical Oncology]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2940861 <![CDATA[Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2943339 11/9/2009 Cancer Prevention Research]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2943339 <![CDATA[Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: A Southwest Oncology Group Study]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2933570 11/9/2009 Annals of Oncology]]> http://www.mdlinx.com/HemeOncLinx/xml-article.cfm/2933570